Search results
Healthy at Every Size? Here's What Doctors Look for Beyond BMI
Verywell Health· 5 days agoLifestyle factors, other disease symptoms, and mental health should all be taken into account as...
DTRA tearing down the Tower of Babel in decentralised clinical trials
Clinical Trials Arena· 5 days agoWhile decentralisation doesn’t have one clear and well-defined path, there is a common denominator...
The Supreme Court limited federal power. Health care is feeling the shockwaves
Missouri Independent· 5 days agoA landmark Supreme Court decision that reins in federal agencies’ authority is expected to hold...
UK Election 2024 explained – How they work, key issues and implications
Financial Express· 6 days agoThere are 650 constituencies in the UK, each represented by a Member of Parliament (MP). On election...
Koo founders on why the social media app is shutting down - The Economic Times
The Economic Times· 6 days agoTiger Global-backed Indian social media app Koo – once seen as a rival to X (previously Twitter) –...
Unveiling the mysteries: PCOD vs PCOS - Times of India
The Times of India· 6 days agoTerms like PCOD (polycystic ovary disease) and PCOS (polycystic ovarian syndrome) can make it...
Indian social media app Koo shuts down: Read CEO’s ‘emotional note’ - Times of India
The Times of India· 6 days agoKoo, India's homegrown microblogging platform with about 10 million active users, is wrapping up its operations after failing to secure crucial partnerships and funding. Co-founders Aprameya ...
Koo app shuts down: Read founder Aprameya Radhakrishna’s full ‘final goodbye’ LinkedIn post
Hindustan Times· 6 days agoMost of them didn't want to deal with user generated content and the wild nature of a social media...
Koo app shuts down after merger negotiations fail; Read founder Aprameya Radhakrishna’s full...
Livemint· 6 days agoKoo, an Indian social media app once seen as a rival to X (formerly Twitter) and backed by American investment firm Tiger Global, is shutting down. Founder Aprameya Radhakrishna announced in a LinkedIn post on Wednesday, July 3.
Left in limbo: When pharma halts rare disease research
Pharmaceutical Technology· 6 days agoAcross three clinical trials conducted in the US and UK, 50 patients with ADA-SCiD were treated with...